PMEL and uveal melanoma: Recently, a TCR-based bi-specific molecule, termed KIMMTRAK by Immunocore, targeted toward the malignant cell surface marker gp100/HLA-A2, fused to an anti-CD3 effector domain, was approved by the FDA for the treatment of unresectable or metastatic uveal melanoma, showing clinical benefit in a phase III clinical trial, via recruitment of T cells to gp100/HLA-A2 positive cells (48, 49).